KVUE:NYSE
Kenvue Inc
$18.39
arrow_downward
-1.87%(-0.35) 1D
$18.46
arrow_upward
+0.38% (+0.070)bedtimeAfter hours
Closed: Sep 8, 4:00:04 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for KVUE...
Open
$18.62
High
$18.65
Low
$18.38
Mkt. cap
35.32B
Avg. vol.
21.27M
Volume
0.00
Dividend
4.57%
Quarterly dividend
$0.21
Ex-dividend date
Aug 12, 2026
P/E ratio
21.32
52-wk high
$20.13
52-wk low
$14.02
EPS
$0.86
Beta
0.46
Shares outstanding
1.92B
No. of employees
22K
Open
$18.62
High
$18.65
Low
$18.38
Mkt. cap
35.32B
Avg. vol.
21.27M
Volume
0.00
Dividend
4.57%
Quarterly dividend
$0.21
Ex-dividend date
Aug 12, 2026
P/E ratio
21.32
52-wk high
$20.13
52-wk low
$14.02
EPS
$0.86
Beta
0.46
Shares outstanding
1.92B
No. of employees
22K
News stories
From web sources and news partners
AD HOC NEWS
·
4 hours ago
Kenvue stock heads into the open after a modest loss
MarketBeat
·
7 hours ago
Kenvue Inc. $KVUE Stock Holdings Increased by Carmignac Gestion
Zacks
·
16 hours ago
Kenvue's Brand Strength and Innovation Strategy Support Growth
Profile
Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and was originally headquartered in the Skillman section of Montgomery Township, New Jersey, before relocating to Summit, New Jersey.
Johnson & Johnson announced in November 2021 that it would spin off its consumer health division as a separate company. The new company was named Kenvue in September 2022, and its initial public offering took place in May 2023, raising $3.8 billion in the largest U.S. IPO since 2021, with an initial valuation of about $41 billion. Johnson & Johnson initially retained more than 90% ownership before completing a full separation through a share exchange in July 2023. Kenvue was subsequently added to the S&P 500 Dividend Aristocrats index.
CEO Thibaut Mongon initially led Kenvue, which employed about 22,200 people in 2022. Following Mongon’s termination in 2025, Kirk Perry was named interim CEO. Wikipedia
About Kenvue Inc
CEOKirk Perry
Employees21.9K
FoundedFeb 23, 2022
HeadquartersSummit, New Jersey, United States
SectorPersonal care products
Websitekenvue.com